The Manufacturers Life Insurance Company Raises Stock Position in AnaptysBio, Inc. (NASDAQ:ANAB)

The Manufacturers Life Insurance Company grew its holdings in shares of AnaptysBio, Inc. (NASDAQ:ANAB) by 66.1% during the third quarter, Holdings Channel reports. The firm owned 42,046 shares of the biotechnology company’s stock after purchasing an additional 16,734 shares during the quarter. The Manufacturers Life Insurance Company’s holdings in AnaptysBio were worth $1,409,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in the company. Frazier Life Sciences Management L.P. increased its stake in shares of AnaptysBio by 140.7% during the second quarter. Frazier Life Sciences Management L.P. now owns 2,165,591 shares of the biotechnology company’s stock worth $54,270,000 after buying an additional 1,265,891 shares during the period. Assenagon Asset Management S.A. increased its stake in shares of AnaptysBio by 55.1% during the third quarter. Assenagon Asset Management S.A. now owns 475,446 shares of the biotechnology company’s stock worth $15,927,000 after buying an additional 168,813 shares during the period. Jennison Associates LLC purchased a new stake in shares of AnaptysBio during the third quarter worth approximately $8,874,000. Victory Capital Management Inc. increased its stake in shares of AnaptysBio by 677.9% during the third quarter. Victory Capital Management Inc. now owns 237,250 shares of the biotechnology company’s stock worth $7,948,000 after buying an additional 206,750 shares during the period. Finally, Charles Schwab Investment Management Inc. increased its stake in shares of AnaptysBio by 3.2% during the third quarter. Charles Schwab Investment Management Inc. now owns 160,321 shares of the biotechnology company’s stock worth $5,371,000 after buying an additional 5,043 shares during the period.

Insider Transactions at AnaptysBio

In other AnaptysBio news, insider Paul F. Lizzul sold 1,500 shares of the stock in a transaction on Monday, September 23rd. The stock was sold at an average price of $38.67, for a total value of $58,005.00. Following the completion of the transaction, the insider now owns 15,398 shares in the company, valued at approximately $595,440.66. This represents a 8.88 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Eric J. Loumeau sold 8,720 shares of the stock in a transaction on Monday, September 16th. The stock was sold at an average price of $39.82, for a total value of $347,230.40. Following the completion of the transaction, the insider now owns 7,020 shares of the company’s stock, valued at $279,536.40. The trade was a 55.40 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 22,440 shares of company stock worth $892,936 over the last 90 days. 33.70% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on the stock. HC Wainwright cut their target price on shares of AnaptysBio from $55.00 to $52.00 and set a “buy” rating on the stock in a research note on Wednesday, November 6th. Truist Financial upped their price target on AnaptysBio from $20.00 to $30.00 and gave the company a “hold” rating in a report on Thursday, August 15th. UBS Group upped their price target on AnaptysBio from $23.00 to $33.00 and gave the company a “neutral” rating in a report on Wednesday, October 30th. BTIG Research downgraded AnaptysBio from a “buy” rating to a “neutral” rating in a report on Monday, December 2nd. Finally, Guggenheim upped their price target on AnaptysBio from $75.00 to $90.00 and gave the company a “buy” rating in a report on Monday, October 21st. Three equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $54.64.

AnaptysBio Trading Up 0.9 %

ANAB stock opened at $23.09 on Wednesday. The company has a market capitalization of $702.63 million, a P/E ratio of -3.80 and a beta of -0.11. AnaptysBio, Inc. has a twelve month low of $15.84 and a twelve month high of $41.31. The business has a 50 day simple moving average of $26.72 and a 200-day simple moving average of $29.68.

AnaptysBio (NASDAQ:ANAB) last released its quarterly earnings results on Tuesday, November 5th. The biotechnology company reported ($1.14) EPS for the quarter, topping the consensus estimate of ($1.72) by $0.58. AnaptysBio had a negative return on equity of 287.94% and a negative net margin of 289.75%. The business had revenue of $30.02 million during the quarter, compared to analysts’ expectations of $7.92 million. Research analysts predict that AnaptysBio, Inc. will post -6.02 EPS for the current fiscal year.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.